Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 4,073 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Self-study Clear all

Conditions: Cholangiocarcinoma
Interventions: Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice; Drug
Lead sponsor: TransThera Sciences (Nanjing), Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 19
States / cities: Santa Monica, California • Stanford, California • Westwood, Los Angeles, California + 14 more

Conditions: Cholesterol, Triglycerides, Omega-3, Eicosapentaenoic Acid
Interventions: AlmegaPL (FDA NDIN # 826); Dietary Supplement
Lead sponsor: Qualitas Health; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Tempe, Arizona • Houston, Texas

Conditions: Smoking
Interventions: Counseling, Self-help guide, Pharmacotherapy, Genetic feedback, verbal, Genetic feedback, printed; Behavioral · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Menlo Park, California • Stanford, California • Seattle, Washington

Conditions: Advanced Epithelial Ovarian, Recurrent Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Carcinoma
Interventions: Enzalutamide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Metastatic Brain Tumor, Cerebral Metastases
Interventions: Physical Activity, Cognitive rehabilitation; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Opioid-use Disorder
Interventions: PCP brief advice, Video doctor, Telephone health coaching, Nurse Care Manager (NCM) intervention; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Acne Vulgaris
Interventions: Tretinoin Gel Microsphere, 0.1%, RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%, Placebo Control; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 973 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Gestational Diabetes
Interventions: Intervention; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Raleigh, North Carolina

Conditions: Depression
Interventions: Step Up Wellness Program, Usual care; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer, Obesity, Weight Changes
Interventions: behavioral dietary intervention, Exercise intervention; Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 50 Years to 75 Years · Female only
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Heart Failure
Interventions: Cell Phone; Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Paroxysmal Supraventricular Tachycardia
Interventions: Etripamil, Placebo, Etripamil Test Dose; Drug
Lead sponsor: Milestone Pharmaceuticals Inc.; Other
Eligibility: 18 Years and older
Enrollment: 1,097 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 54
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 44 more

Conditions: Falls, Balance Self-confidence
Interventions: Medical QiGong training; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Fatigue, Self Efficacy, Quality of Life, Physical Activity, Lung Cancer, Non-Small Cell Lung Cancer
Interventions: Light Physical Activity 1, Light Physical Activity 2, Support Education Activity; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Health Knowledge, Attitudes, Practice
Interventions: Meditation with guided tea consumption, Breathing meditation; Other
Lead sponsor: Otsuka Holdings Co., Ltd.; Industry
Eligibility: 20 Years to 49 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Generalized Anxiety Disorder
Interventions: Empower Neuromodulation System; Device
Lead sponsor: Theranova, L.L.C.; Industry
Eligibility: 19 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Preeclampsia, Gestational Hypertension
Interventions: spironolactone 25 mg orally once daily, Placebo tablet to match spironolactone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Emotional Distress, Impulsive Behavior, Mood Lability, Mood Instability, Rumination, Psychopathology, Affective Symptoms
Interventions: Neurobehavioral Affective Control Training; Behavioral
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Parents Who Have Lost a Child to Cancer
Interventions: Questionnaires/Interviews; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2027
U.S. locations: 2
States / cities: Bethesda, Maryland • New York, New York

Conditions: Contraception
Interventions: Household Visits, Small Groups; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 13 Years and older
Enrollment: 2,898 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Efavirenz, Stavudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: San Diego, California • Dallas, Texas

Conditions: Xerostomia, Head and Neck Cancer
Interventions: Bone Marrow Aspiration, Ultrasound Imaging of Salivary Glands, Salivary Assay, Quality of Life Instruments; Procedure · Diagnostic Test · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 89 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Parkinson Disease
Interventions: Non-invasive brainstem stimulation; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Behavioral Pharmacology of Cannabis
Interventions: Oral Delta-8-THC Cannabis, Oral Delta-9-THC Cannabis, Oral Placebo, Vaporized Delta-8-THC Cannabis, Vaporized Delta-9-THC Cannabis, Vaporized Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

AlmegaPL CV Health Open Label Study

Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.

Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies

Impact of Cognitive Rehab and Physical Activity on Cognition in Patients With Metastatic Brain Tumors Undergoing RT

Subthreshold Opioid Use Disorder Prevention (STOP) Trial

A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris

Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants

Effectiveness of The Step Up Wellness Program for People With Depression

Effect of a Low-Calorie Diet and/or Exercise Program on Risk Factors for Developing Breast Cancer in Overweight or Obese Postmenopausal Women

A Novel Fully Integrated Mobile Management Solution Using Cell Phone Technology for Heart Failure

Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).

Medical Qigong for Mobility and Balance Self-Confidence

Understanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom Experience

A Study Investigating the Effects of a Novel Mindfulness Approach on Frequency and Duration of Meditation and Self-Reported Stress and Mood in Generally Healthy Adults

Empower Neuromodulation System - Pilot Study for Anxiety Treatment

Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories

Neurobehavioral Affective Control Training

Understanding the Psychosocial Needs of Parents Who Have Lost a Child to Cancer

Evaluating Household Visits and Small Groups to Increase Contraception Use Among Married Adolescent Girls in Rural Niger

A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly

Salivary Gland Autotransplantation for Treatment of XRT Induced Xerostomia

Use of a Non-Invasive Brainstem Neuromodulation Device to Improve Neurovascular Status in Parkinson's Disease

Comparative Pharmacokinetic and Pharmacodynamic Effects of Delta-8 and Delta-9 THC